Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Stephen M Ansell, MD PhD, Ian W. Flinn, MD PhD, Michael B. Maris, MD, Owen A. O'Connor, MD, PhD, Alexander Lesokhin, MD, Anjali S. Advani, MD, Mark D. Minden, MD PhD, Mary Beth M. Percival, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Meghan Irwin, BSc, EMBA, Penka S. Petrova, PhD, Robert A. Uger, PhD, Eric L Sievers, MD, Robert W. Chen, MD

Blood (2017) 130 (Supplement 1): 4116.

https://doi.org/10.1182/blood.V130.Suppl_1.4116.4116

Published: 2017

Journal Articles

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

Christiane Querfeld, MD PhD, John Thompson, MD, Matthew Taylor, Raju Pillai, MD, Lisa DS Johnson, PhD, Tina Catalano, MSc, Penka S. Petrova, PhD, Robert A. Uger, PhD, Meghan Irwin, BSc, EMBA, Eric L Sievers, MD, Oleg E. Akilov, MD

Blood (2017) 130 (Supplement 1): 4076.

https://doi.org/10.1182/blood.V130.Suppl_1.4076.4076

Published: 2017

Journal Articles

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen Ansell, MD PhD, Robert W Chen, MD, Ian W. Flinn, MD PhD, Michael B. Maris, MD, Owen A. O'Connor, MD PhD, Lisa DS Johnson, PhD, Meghan Irwin, Penka S. Petrova, PhD, Robert A. Uger, PhD, Eric L Sievers, MD

Blood (2016) 128 (22): 1812.

https://doi.org/10.1182/blood.V128.22.1812.1812

Published: 2016

Journal Articles

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Ajay K. Gopal, MD, Robert Chen, MD, Scott E. Smith, MD, PhD, Stephen M Ansell, M.D.Ph.D., Joseph D Rosenblatt, MD, Kerry J. Savage, MD, MSc, Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dirk Huebner, MD, Eric L. Sievers, MD, Anas Younes, MD

Blood (2013) 122 (21): 4382.

https://doi.org/10.1182/blood.V122.21.4382.4382

Published: 2013

Journal Articles

Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Ajay K. Gopal, MD, Scott E. Smith, MD, PhD, Stephen M. Ansell, M.D., Ph.D., Joseph D. Rosenblatt, MD, Kerry J. Savage, MD MSc, Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Eric L. Sievers, MD, Anas Younes, MD

Blood (2012) 120 (21): 3689.

https://doi.org/10.1182/blood.V120.21.3689.3689

Published: 2012

Journal Articles

Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study,

Jeffrey E. Lancet, MD, Mikkael A. Sekeres, MD, MS, Brent L. Wood, MD, PhD, Laurie E. Grove, PA-C, Larissa Sandalic, MS, Eric L. Sievers, MD, Joseph G. Jurcic, MD

Blood (2011) 118 (21): 3613.

https://doi.org/10.1182/blood.V118.21.3613.3613

Published: 2011

Journal Articles

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Andrei R. Shustov, MD, Ranjana Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, MD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Eric L. Sievers, MD, Dana A. Kennedy, PharmD, Barbara Pro, MD

Blood (2010) 116 (21): 961.

https://doi.org/10.1182/blood.V116.21.961.961

Published: 2010

Journal Articles

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert Chen, Ajay K. Gopal, MD, Scott E. Smith, MD, PhD, FACP, Stephen M. Ansell, MD, PhD, Joseph D. Rosenblatt, MD, Richard Klasa, MD, CM, FRCP(C), Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dana A. Kennedy, PharmD, Eric L. Sievers, MD, Anas Younes, MD

Blood (2010) 116 (21): 283.

https://doi.org/10.1182/blood.V116.21.283.283

Published: 2010

Journal Articles

The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.

Michelle Fanale, MD, Nancy L Bartlett, MD, Andres Forero-Torres, MD, Joseph Rosenblatt, MD, Sandra J Horning, MD, Anna R Franklin, MD, Carmel M Lynch, PhD, Eric L Sievers, MD, Dana A Kennedy, PharmD, BCOP

Blood (2009) 114 (22): 2731.

https://doi.org/10.1182/blood.V114.22.2731.2731

Published: 2009

Journal Articles

Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.

Azra Raza, MD, Joseph G. Jurcic, MD, Gail J. Roboz, MD, Michael Maris, MD, Joseph Stephenson, MD, Brent L. Wood, MD, Bhaskar Rege, PhD, Laurie E. Grove, PA-C, Jonathan G. Drachman, MD, Eric L. Sievers, MD

Blood (2007) 110 (11): 159.

https://doi.org/10.1182/blood.V110.11.159.159

Published: 2007

Journal Articles

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

May S.K. Sutherland, PhD, Changpu Yu, MD, Carol Morris-Tilden, Timothy S. Lewis, PhD, Jamie B. Miyamoto, Julie A. McEarchern, PhD, Ezogelin Oflazoglu, PhD, Hanspeter Gerber, PhD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2007) 110 (11): 919.

https://doi.org/10.1182/blood.V110.11.919.919

Published: 2007

Journal Articles

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

May S.K. Sutherland, PhD, Timothy S. Lewis, PhD, Changpu Yu, MD, Julie A. McEarchern, PhD, Jonathan G. Drachman, MD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2006) 108 (11): 1995.

https://doi.org/10.1182/blood.V108.11.1995.1995

Published: 2006

Journal Articles

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Azra Raza, MD, Joseph G. Jurcic, MD, Gail J. Roboz, MD, Joseph J. Stephenson, MD, Mark U. Rarick, MD, Brent L. Wood, MD, Laurie E. Grove, PA-C, Eric L. Sievers, MD, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 4568.

https://doi.org/10.1182/blood.V108.11.4568.4568

Published: 2006

NARROW

TTI-621 (SIRPαFc), an Immune Checkpoint Inhibitor Blocking the CD47 “Do Not Eat” Signal, Induces Objective Responses in Patients with Advanced, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 "Do Not Eat" Signal

A Phase 1 Study of TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study,

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.

Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33.

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only